ViroGates nets DKK60mm through IPO on Nasdaq First North
Executive Summary
In its oversubscribed initial public offering on Nasdaq First North Denmark, ViroGates AS (prognostic biomarker tools used in clinical decision making) sold 824k new shares at DKK91 apiece, for net proceeds of DKK60mm ($9.38mm).
Deal Industry
- Biotechnology
- In Vitro Diagnostics
- Laboratory Testing Services
- Services
-
Medical Devices
- Diagnostic Equipment & Supplies
-
In Vitro Diagnostics
- Chemistry, Immunoassay
Deal Status
- Final
Deal Type
-
Financing
- IPO
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice